Alexandra Langlais nackt sorted by
relevance

Admin22.07.2021

Mesothelioma: Langlais, Alexandra

Although taxan-based therapy shows poorest PFS in first-line, no chemotherapy regimen was associated with prognosis.
3007
Admin13.08.2021

Mesothelioma: Langlais, Alexandra

received personal fees from Astra Zeneca, Roche, Bristol—Myers Squibb, Takeda, Pfizer, Boehringer Ingelheim, and Novartis.
2901
Admin17.08.2021

France: Langlais, Alexandra

Among patients whose relative ctDNA abundance was below the median, those treated with atezolizumab tended to have higher OS than those in the chemotherapy arm.
1701
Admin27.07.2021

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Patients harboring KRAS mutations plus another alteration had an OS time 13.
3406
Admin17.09.2021

Mesothelioma: Langlais, Alexandra

14 Service de Pneumologie, 58 Rue Montalembert, CHU G Montpied, 63000 Clermont Ferrand, France.
51010
Admin31.07.2021

France: Langlais, Alexandra

Patients with detectable ctDNA had a significantly lower disease control rate at week 6 compared with patients with no detectable ctDNA, regardless of the nature of the treatment.
6702
Admin03.08.2021

Mesothelioma: Langlais, Alexandra

received personal fees from AbbVie, Bristol—Myers Squibb, Boehringer Ingelheim, Astra Zeneca, Roche, Novartis, MSD, Pfizer, and Takeda.
3804
Admin26.06.2021

France: Langlais, Alexandra

RESULTS: We identified 162 patients 0.
5806
Admin15.07.2021

Mesothelioma: Langlais, Alexandra

The purpose of the present study was to determine whether circulating tumor DNA ctDNA , prospectively collected at treatment initiation, was associated with the prognosis of SCLC, and whether it identified patients who benefited from atezolizumab.
3403
Admin06.07.2021

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

78 , and objective response rate under first-line chemotherapy 41.
1900